

Effective Date: 6/2017
Last Reviewed: 2/2020, 2/2021, 1/2022, 3/2023
Scope: Medicaid

## RISPERDAL CONSTA (risperidone long-acting injection)

### POLICY

#### I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

##### FDA-Approved Indication

##### **Schizophrenia**

Risperdal Consta is indicated for the treatment of schizophrenia.

##### **Bipolar Disorder**

Risperdal Consta is indicated as monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of Bipolar I Disorder

All other indications are considered experimental/investigational and are not a covered benefit.

#### II. CRITERIA FOR APPROVAL

An authorization may be granted for 12 months when the following criteria (A) and (B) are met:

- A. Tolerability with oral risperidone has been established
- B. The requested drug is being prescribed for one of the following:
  - o Treatment of schizophrenia
  - o As monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of bipolar I disorder

#### III. REFERENCES

1. Risperdal Consta [package insert]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; February 2021 .
2. Lexicomp Online, AHFS DI (Adult and Pediatric) Online. Hudson, OH: Wolters Kluwer Clinical Drug Information, Inc. <http://online.lexi.com/>. Accessed February 2020.
3. Micromedex (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA. <http://www.micromedexsolutions.com/>. Accessed February 2020.
4. American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia, 2<sup>nd</sup> edition. 2010. Available at: [http://psychiatryonline.org/pb/assets/raw/sitewide/practice\\_guidelines/guidelines/schizophrenia.pdf](http://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/schizophrenia.pdf). Accessed September 2019.